RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus
Calgary, Alberta (ots/PRNewswire) - In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism. Resverlogix Corp. announced today findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in ...